Table IV.
Distribution of CCR5Δ32 allele as a function of clinical outcome in WNV-seropositive patients
| Genotype, n (%)
|
||||||
|---|---|---|---|---|---|---|
| All racial groups
|
Self-reporting Caucasians
|
|||||
| Clinical outcome | +/+ | +/Δ32 | Δ32/Δ32 | +/+ | +/Δ32 | Δ32/Δ32 |
| Fevera | 85 (83.3) | 12 (11.8) | 5 (4.9) | 52 (80.0) | 9 (13.8) | 4 (6.2) |
| Meningitisa | 100 (81.3) | 19 (15.4) | 4 (3.3) | 59 (78.7) | 13 (17.3) | 3 (4.0) |
| Encephalitisa | 82 (71.9) | 27 (23.7) | 5 (4.4) | 48 (68.6) | 17 (24.3) | 5 (7.1) |
| Not Specifieda | 49 (87.5) | 4 (7.1) | 3 (5.4) | 5 (100.0) | 0 (0) | 0 (0) |
| Death | 13 (68.4) | 4 (21.1) | 2 (10.5) | 6 (75.0) | 0 (0) | 2 (25.0) |
| Total | 316 (80.0) | 62 (15.7) | 17 (4.3) | 164 (76.3) | 39 (18.1) | 12 (5.6) |
Data were pooled from the Arizona and Colorado cohorts.
a
Patients were classified into one of the four indicated disease categories by interview with the referring physician. +, wild-type CCR5 allele; Δ32, CCR5Δ32 allele.